Biocon Biologics Gains FDA Approval for Two Denosumab Biosimilars Bosaya and Aukelso

Biocon Biologics Ltd. has received approval from the U.S. Food and Drug Administration (FDA) for two biosimilar products, Bosaya and Aukelso, both of which are denosumab biosimilars. The announcement was made on September 17, 2025, by the Bengaluru-based company, a subsidiary of Biocon Ltd., which specializes in developing and manufacturing biosimilars for global markets.

The FDA’s approval marks a significant regulatory milestone for Biocon Biologics as it expands its portfolio in the U.S. market. Denosumab is commonly used to treat conditions such as osteoporosis and bone-related complications associated with cancer. The approval of Bosaya and Aukelso positions these products as alternatives to existing branded treatments, offering healthcare providers additional options for managing these conditions.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: September 17, 2025

Related posts:

Brand-Name Drug List Prices Rise 2.3% in 2024, Net Prices Continue Decline Study Links 3+ Hours of Daily Social Media to Higher Anxiety in Teens LYT-100 Investigated as Potential Treatment for Idiopathic Pulmonary Fibrosis with Differentiated Mechanism of Action Binge Eating on High-Fat, High-Sugar Foods Found to Rewire Brain and Increase Stress-Induced Overeating

Author

Mark Chiang